Boryung Corp

Boryung Corp maintains a relatively strong liquidity position, with a current ratio of 2.6, indicating the company can cover its short-term liabilities more than twice over. However, the company's liquidity risk is assessed as medium, and its net cash position is negative after subtracting total debt, suggesting potential pressure on short-term financial flexibility. The company's debt-to-equity ratio of 0.39 reflects a conservative capital structure, with long-term debt accounting for a significant but manageable portion of its liabilities. In terms of profitability, Boryung Corp's return on equity (ROE) of 7.61% and return on assets (ROA) of 4.63% are in line with industry norms, though the company's operating margin and net margin are not explicitly provided. The gross profit margin of 36.6% (calculated from gross profit and revenue) suggests the company is effectively managing production costs. The company's operating income of 66.4 billion KRW and net income of 64.3 billion KRW indicate a healthy bottom-line performance. Geographically, Boryung Corp's revenue is concentrated in South Korea, as no international revenue breakdown is provided in the available data. The company's business is primarily driven by its domestic pharmaceutical operations, with no disclosed segments or product lines beyond this. This concentration may expose the company to regulatory and economic risks specific to the South Korean market. The company's growth trajectory is not explicitly outlined in the available data, but its revenue of 1.02 trillion KRW and operating cash flow of 133.2 billion KRW suggest a stable financial position. Analysts have set a uniform price target of 12,000 KRW, with no variance in estimates, indicating a consensus on the company's valuation. The company's free cash flow of 69.5 billion KRW and capital expenditure of -29.9 billion KRW (representing a reduction in capital spending) suggest a focus on maintaining rather than expanding operations. Risk factors for Boryung Corp include its medium liquidity risk and the potential for dilution, though the latter is assessed as low. The company's negative net cash position after subtracting total debt raises concerns about its ability to fund operations without external financing. No recent events, such as filings or transcripts, are provided in the available data to indicate material changes in the company's risk profile. Analysts have not provided specific guidance on the company's future earnings or revenue, but the uniform price target of 12,000 KRW suggests a stable outlook. The company's recent financial performance, including its operating income and net income, supports this stability. No specific guidance is available for the company's R&D or capital expenditure plans in the near term.